MGNX vs DSC Comparison

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

DSC Holdings Ltd is an AI application infrastructure for China's used car industry. According to CIC, the Company has held over 90% market share in operating systems for China's used car dealers, giving it nationwide dealer connections and massive, granular, proprietary, real-time industry data. Building on this digital foundation, the group further supports used car dealers with essential transaction services across their workflows. Its Services engage and benefit thousands of dealer collaborators, such as inspectors, transporters, and other internet platforms, creating an ecosystem with used car dealers at its center.